Table I.
Clinical and demographic characteristics of patients
| Clinical and demographic features | Intention-to-treat group (n=60) | Post-exclusion for enrolment error modified intention-to-treat group (n=49)* | ||
|---|---|---|---|---|
| Control (n=30) | Nasal CQN (n=30) | Control (n=25) | Nasal CQN (n=24) | |
| Age (yr), mean±SD | 34.2±9.4 | 35.6±11.3 | 34.4±9.4 | 35.41±11.7 |
| Range | 18-58 | 18-58 | 18-58 | 18-58 |
| Sex | ||||
| Male | 21 | 26 | 17 | 21 |
| Female | 6 | 4 | 5 | 3 |
| Transgender | 3 | 0 | 3 | 0 |
| Comorbidities | 1 | 0 | 1 | 0 |
| Smoking/oral tobacco | ||||
| Yes | 6 | 3 | 5 | 3 |
| Quit | 1 | 0 | 1 | 0 |
| Never | 23 | 27 | 19 | 21 |
| BCG vaccination | 30 | 28 | 25 | 22 |
| Contact history | ||||
| Known | 21 | 20 | 18 | 16 |
| Unknown | 9 | 10 | 7 | 8 |
| Symptoms at presentation | ||||
| Asymptomatic | 23 | 24 | 20 | 18 |
| Symptomatic | 7 | 6 | 5 | 6 |
| Days since symptomatic (n=13) | 5.6 | 5 | 3.4 | 5 |
| Median (range) | 3 (2-12) | 3 (1-10) | 3 (2-5) | 3 (1-10) |
| Breath holding time at presentation (sec), mean±SD | 28.5±0.5 | 29.1±0.44 | 28.6±2.8 | 29.2±2.6 |
| NEWS at presentation | ||||
| 0 | 28 | 28 | 24 | 22 |
| 1 | 2 | 1 | 1 | 1 |
| 2 | 0 | 1 | 0 | 1 |
| NEWS progression | ||||
| 0→1 | 1 | 0 | 0 | 0 |
| 0→2 | 0 | 0 | 0 | 0 |
| 1→2 | 0 | 0 | 0 | 0 |
| 2→3 | 0 | 0 | 0 | 0 |
*Modified intention-to-treat group- excluding patients with day 0 RT-PCR negative for COVID-19 (n=11). CQN, chloroquine; SD, standard deviation; BCG, bacille Calmette-Guerin; RT-PCR, reverse transcription-polymerase chain reaction; NEWS, National Early Warning Score